TGA Investigates COVID-19 Tests and Emerging Variants

By Sam | February 4, 2021

Australia’s Therapeutic Goods Administration is conducting a postmarket review of all COVID-19 point-of-care and laboratory tests listed in the Australian Register of Therapeutic Goods to ensure that they can detect emerging SARS-CoV-2 genetic variants.
Source: The GMP Letter

Posted in The GMP Letter